Purpose: Despite increasing use of oxycodone/naloxone controlled-release (CR) in Australia, little is known about how it has affected the overall oxycodone CR market since its subsidy in 2011. Conclusions: After its subsidy, the uptake of low-dose oxycodone/naloxone CR was greater than expected if it were substituting the single-ingredient oxycodone CR, resulting in an expansion of the oxycodone CR market.
| INTRODUCTION
Oxycodone with naloxone controlled-release (CR) tablets are fixeddose combination products with equivalent analgesia and similar adverse effects to single-ingredient oxycodone CR tablets of the same strength.
1-3 The addition of naloxone, an opioid antagonist that blocks opioid receptors in the gut, reduces but does not eliminate constipation, a common adverse effect of opioid therapy. 4, 5 Oxycodone/naloxone CR is only one of a growing number of new opioid products marketed in recent years. 6 In the United States, oxycodone/naloxone CR was approved by the Food and Drug Administration in 2014 and given abuse-deterrent labelling; however, it was never marketed, and marketing plans have now been abandoned. 6 In Canada, oxycodone/naloxone CR is approved by the regulator, but it is not subsidised on any of the provincial formularies so uptake has been limited. 7 In 2011, oxycodone/naloxone CR was publicly subsidised in Australia and is available at a similar cost to patients as the single-ingredient oxycodone CR; as of April 2014, it is the only low-dose (≤5 mg) oxycodone CR tablet on the market. Australia's unique context allows for an examination of the impact of oxycodone/naloxone CR on overall oxycodone CR utilisation. Furthermore, in contrast to North America where much of the focus has been on the product's abuse-deterrent properties, oxycodone/naloxone CR is marketed heavily in Australia as a solution to opioid-induced constipation. 8, 9 Australian data suggest that there has been a change in the utilisation patterns of oxycodone CR, coinciding with the introduction of oxycodone/naloxone CR. First, dispensing of the single-ingredient oxycodone CR has been decreasing, but oxycodone/naloxone CR has increased rapidly. 10, 11 Further, recent data show that while the number of oxycodone dispensings and people being dispensed oxycodone are increasing, the total volume (as measured in milligrams of oxycodone dispensed) is not. 12 Therefore, the objective of this study was to document the uptake of oxycodone/naloxone CR and how it has affected overall trends in utilisation of oxycodone CR formulations as a whole. We sought to determine whether oxycodone/naloxone CR is being used as a substitute for the single-ingredient oxycodone CR or whether it is being prescribed to an expanding patient population. We used an interrupted time series analysis and a retrospective cohort study to examine the impact of the subsidy of oxycodone/naloxone CR on (a) population-level dispensing of all oxycodone CR formulations, (b) new oxycodone CR treatment episodes, and (c) patterns of opioid utilisation among people initiating on oxycodone CR formulations over time.
2 | METHODS
| Key events of interest
In December 2011, oxycodone/naloxone CR was subsidised in
Australia for treatment of chronic severe disabling pain, the same indication as the single-ingredient oxycodone CR. 13 On April 1, 2014, the single-ingredient oxycodone CR (≥10 mg) was reformulated to be tamper resistant and the 5-mg strength was withdrawn from the Australian market by the manufacturer. From this date oxycodone/naloxone CR was the only 5-mg oxycodone CR formulation available.
| Setting
In Australia, all citizens and permanent residents are entitled to subsidised access to prescribed medicines through the Pharmaceutical Benefits Scheme (PBS), serving the general population, and the Repa- 
KEY POINTS
• We observed rapid uptake of oxycodone/naloxone CR in Australia since its subsidy in 2011; in 2016, it was the most commonly dispensed oxycodone CR formulation for new treatment episodes (91.4%).
• Growth in dispensing of oxycodone CR was 1.6-fold faster than prior to subsidy of oxycodone/naloxone CR, driven primarily by an increase in dispensing of low strength (≤5 mg) formulations.
• We defined a new treatment episode as a dispensing of any oxycodone CR formulation (single-ingredient oxycodone CR or oxycodone/naloxone CR) with no dispensing of either formulation in the 12 months prior; individuals could have been dispensed a different opioid during this time. Individuals could appear more than once if they initiated multiple treatment episodes that met this criterion.
We restricted the population to concessional beneficiaries to ensure complete capture of dispensed medicines during the study period.
Approximately 25% of Australians are concession card holders and primarily includes people greater than or equal to 65 years, people with low incomes, and people with disabilities. Approximately 75% of all oxycodone CR dispensings are to concessional beneficiaries. 16 To ascertain beneficiary status, individuals had to have been dispensed only medicines attracting concessional subsidy during the study period (12 mo before and after initiation) and have at least one dispensing record for any medicine in the 12 months prior to initiation.
| Change in characteristics of initiators over time
To 
| Trends in new oxycodone treatment episodes
We calculated quarterly counts of new oxycodone CR treatment episodes, overall and by tablet strength (≤5 mg or >5 mg). To quantify changes in the number of new treatment episodes, we performed an interrupted time series analysis as described above.
| Characteristics of initiators over time
We compared the demographic and opioid use characteristics of people initiating in each of the three periods by calculating risk differences adjusted for age and sex using a generalised linear model with a binomial distribution adjusted for correlation within individuals included in more than one time period. All analyses were performed with SAS® V9.4 (SAS Institute Inc, Cary, North Carolina) and R. less than or equal to 5-mg strengths and comprised the majority of the greater than 5-mg strengths (58%). 
| New CR oxycodone treatment episodes

| Impact of oxycodone/naloxone CR subsidy
In the first quarter of the study period (Q2 2006), we observed 1072 new treatment episodes with oxycodone CR, with 21% of these episodes involving the 5-mg tablet strength ( Figure 2 ; Table 3 ).
Immediately after the listing of oxycodone/naloxone CR, we observed an immediate increase (level shift) in the number of new treatment episodes, and the growth rate increased 1.5-fold from 47 to 72 episodes/quarter. This was driven entirely by an increase in initiation with 5-mg oxycodone/naloxone CR, and the growth rate for 5-mg formulations increased 2.6-fold, from 20/quarter to 51/quarter.
We did not observe a change in initiation with greater than 5-mg formulations. By Q1 2014, we observed 2847 new treatment episodes, of which 44% were with a 5-mg strength.
| Impact of the oxycodone CR reformulation/5 mg withdrawal
We observed an immediate increase (level shift) in initiation with 5-mg oxycodone/naloxone CR after the withdrawal of the 5-mg singleingredient oxycodone CR tablet strength CR (Q2 2014); the overall growth rate in initiation increased to 69/quarter. We did not observe any change in initiation with greater than 5-mg oxycodone CR formulations overall. Slope unchanged from previous period.
| Characteristics of initiators over time
In period 3, we observed a large increase in initiation with less than or equal to 5-mg tablet strengths; nearly half (49.8%) of new treatment episodes involved less than or equal to 5-mg strengths compared with 26.8% in period 1 (Table 5) . In absolute numbers, this is a nearly 4-fold increase in the number of people initiating on low strengths (less than or equal to 5 mg) (1946 to 7508). However, the number of people initiating on strengths greater than or equal to 20 mg decreased, both in absolute and relative terms. In period 3, individuals were also less like to be dispensed a weak opioid prior to initiation (RD = −7.9%, 95% CI, −9.2% to −6.7%) and less likely to continue with opioid therapy in the 90 days after initiation (RD = −8.8%, 95% CI, −10.2% to −7.4). People initiating in period 3
were also dispensed a smaller amount of oxycodone CR compared with period 1.
| DISCUSSION
We observed a rapid uptake of oxycodone/naloxone CR after its subsidy, and it is currently the main formulation of oxycodone CR dispensed in Australia. Oxycodone/naloxone CR is now the only low strength (≤5 mg) oxycodone CR on the market, yet dispensing of less than or equal to 5-mg formulations has been increasing at a rate greater than would be expected if it were simply substituting for the single-ingredient oxycodone CR.
Similarly, we observed that decreases in use of greater than 5-mg single-ingredient oxycodone CR after introduction of the tamper-resistant formulation have been offset by increases in oxycodone/naloxone CR. As a result, overall growth in use of oxycodone CR is increasing.
Several factors are likely driving this increase. First, oxycodone/naloxone CR has potential (although unproven)
abuse-deterrent properties. 18 Consequently, recent reports suggest that several Australian pain services are now prescribing oxycodone/naloxone CR in preference to other formulations. [19] [20] [21] However, given the observed decline in use of the tamper-resistant single-ingredient oxycodone CR, it is likely that much of the increased uptake of oxycodone/naloxone CR is related to its effects on opioid-induced constipation. Indeed, the observed uptake of oxycodone/naloxone CR was greatest in older individuals, who often On the basis of the rapid uptake of oxycodone/naloxone CR, there appears to be a real or perceived need for opioids that reduce the risk of constipation. Opioid-induced constipation is a well-known and common adverse effect of chronic pain treatment and can negatively affect quality of life. 22 To our knowledge, the oxycodone/naloxone CR combination is the only opioid containing naloxone designed to treat constipation primarily marketed as such, rather than for opioid dependence or abuse deterrence. In
Israel, oxycodone/naloxone CR is also marketed for treatment of constipation, and the use of the combination has likewise been increasing while the single-ingredient product is decreasing. 23 Regardless, the proven benefits of oxycodone/naloxone CR are predominantly for the treatment of pre-existing opioid-induced constipation, whereas it has only shown only a small benefit for prevention. 24 In recent years, we also observed an increase in the number of people initiating with low-strength oxycodone CR, in preference to weak opioids. While Australian guidelines recommend initiation with the lowest available strength, 25 we observed no reduction in the number of people initiating with higher tablet strengths and an increase in overall initiation with oxycodone CR. Together, this indicates an expansion of the oxycodone CR market after subsidy of oxycodone/naloxone CR and may signify a change from other strong opioids to oxycodone CR. However, we observed no increase in the proportion of initiators who had previous use of other strong opioids, suggesting that switching was minimal. As our study has focussed only on oxycodone CR, we cannot say whether the observed trends are specific to oxycodone, or reflect more general trends in opioid use. Nonetheless, recent Australian data have shown that there has been a decrease in the number of people using weak opioids and an increase in people using strong opioids only. 12 Further research will be needed to determine whether these changes have had any impact on opioid-related adverse events.
It is also noteworthy that there has been an increase in one-off oxycodone CR dispensing, with no other opioid dispensings in the 90 days before or after. In Australia, opioid CR formulations are only subsidised for the treatment of refractory chronic, severe, disabling pain. 13 Initiation with a long-acting formulation, particularly in the elderly, is not recommended because of the increased risk of unintentional overdose and respiratory depression. 26, 27 In addition, a single dispensing may indicate either poor tolerability, or off-label use for acute pain. Since our data do not contain any information about the indication for treatment, we cannot draw any conclusions about the appropriateness of prescribing. However, previous research has found that in Australian general practice, the majority of opioids are prescribed for nonchronic conditions (such as musculoskeletal pain) 28 and that compliance with opioid prescribing guidelines is poor. 29 Thus, it is worrisome that we observed patterns of use that are suggestive of inappropriate use and warrant further investigation. We observed a rapid uptake of oxycodone/naloxone CR following its subsidy in 2011, almost completely replacing oxycodone CR for new treatment episodes, particularly among older people. This is likely attributable to its perceived benefits for prevention of opioid-induced constipation and the greater availability of less than or equal to 5-mg formulations that are no longer available in the single-ingredient formulation. While substitution of the single-ingredient oxycodone CR with oxycodone/naloxone CR was to be expected, overall use and initiation with oxycodone CR has been growing at a faster rate than before the subsidy of oxycodone/naloxone CR, with a shift towards use of lower tablet strengths and a lower volume.
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